BR9604989A - Polipeptídeos modificados para imunogenicidade aperfeiçoada e processo de sua produção - Google Patents

Polipeptídeos modificados para imunogenicidade aperfeiçoada e processo de sua produção

Info

Publication number
BR9604989A
BR9604989A BR9604989-8A BR9604989A BR9604989A BR 9604989 A BR9604989 A BR 9604989A BR 9604989 A BR9604989 A BR 9604989A BR 9604989 A BR9604989 A BR 9604989A
Authority
BR
Brazil
Prior art keywords
polypeptide
improved immunogenicity
production process
modified
modified polypeptides
Prior art date
Application number
BR9604989-8A
Other languages
English (en)
Inventor
Nicolas Joseph Fasel
Christophe Dominique Reynond
Original Assignee
Rmf Dictagene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rmf Dictagene Sa filed Critical Rmf Dictagene Sa
Publication of BR9604989A publication Critical patent/BR9604989A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

POLIPEPTìDEOS MODIFICADOS PARA IMUNOGENICIDADE APERFEIçOADA E PROCESSO DE SUA PRODUçãO. A invenção se refere a um polipeptídeo recombinante apresentando imunogenicidade aperfeiçoada, compreendendo uma estrutura de glicosil-fosfatidilinositol. O polipeptídeo é, por exemplo, um antígeno, tal como um polipeptídeo parasita, em particular um polipeptídio Plasmodium falciparum, tal como a proteína do circunsporozoito (CPS). A invenção se refere ainda a um vetor de DNA recombinante para expressar o pilpeptídeo, processos para a indução de uma imuno-resposta dirigida a um ou mais epítopos do polipeptídeo, e processos para a produção das vacinas de polipeptídeos modificados, compreendendo o polipeptídeo.
BR9604989-8A 1995-04-25 1996-04-25 Polipeptídeos modificados para imunogenicidade aperfeiçoada e processo de sua produção BR9604989A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/428,616 US6113917A (en) 1995-04-25 1995-04-25 Modified polypeptides for enhanced immunogenicity
EP95201066 1995-04-25
NL1001348A NL1001348C2 (en) 1995-04-25 1995-10-05 Polypeptide comprising glycosyl-phosphatidyl:inositol structure
PCT/EP1996/001744 WO1996034105A1 (en) 1995-04-25 1996-04-25 Modified polypeptides for enhanced immunogenicity

Publications (1)

Publication Number Publication Date
BR9604989A true BR9604989A (pt) 1999-11-30

Family

ID=26139248

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9604989-8A BR9604989A (pt) 1995-04-25 1996-04-25 Polipeptídeos modificados para imunogenicidade aperfeiçoada e processo de sua produção

Country Status (15)

Country Link
US (1) US6113917A (pt)
EP (1) EP0826050A1 (pt)
JP (1) JPH11504215A (pt)
AU (1) AU714808B2 (pt)
BR (1) BR9604989A (pt)
CA (1) CA2218987A1 (pt)
CZ (1) CZ291013B6 (pt)
HU (1) HUP9802238A3 (pt)
IL (1) IL118021A0 (pt)
NL (1) NL1001348C2 (pt)
NO (1) NO974924L (pt)
NZ (1) NZ307195A (pt)
PL (1) PL323078A1 (pt)
WO (1) WO1996034105A1 (pt)
ZA (1) ZA963269B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026911A1 (en) * 1996-01-29 1997-07-31 Georgetown University Malaria vaccine based upon the addition of a msa1 peptide
AUPP589398A0 (en) * 1998-09-14 1998-10-08 Walter And Eliza Hall Institute Of Medical Research, The Immunogenic compositions and uses thereof
AUPP675898A0 (en) * 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of activating t cells and agents useful for same
KR20050035511A (ko) * 2001-10-13 2005-04-18 아스테리온 리미티드 폴리펩타이드들을 포함하는 글리코실포스파티딜이노시톨
US20030171260A1 (en) * 2002-03-11 2003-09-11 Nelson Deanna Jean Compositions and methods utilizing hydroxamates to scavenge oxidant toxins
BR0312985A (pt) 2002-07-26 2005-06-21 Inst Medical W & E Hall Métodos para extrair ou induzir, em um mamìfero, uma resposta imune dirigida a um parasita, para tratar de modo terapêutico ou profilático um mamìfero para infecção por parasitas, para o tratamento e/ou a profilaxia de uma condição doentia de mamìfero, uso de uma composição,composição, composição de vacina, composição farmacêutica, anticorpo para inibir, parar ou retardar o inìcio ou progressão de uma condição doentia de mamìfero, uso de um anticorpo, métodos para detectar, em uma amostra bológica, uma molécula imunointerativa dirigida a um microorganismo e para detectar, monitorar ou de outra forma avaliar uma resposta imune dirigida a um microorganismo em um indivìduo, kit modular, método para analisar, projetar e/ou modificar um agente capaz de interagir com um sìtio de ligação de molécula imunointerativa anti-gpi glicano, e, uso do agente
WO2004090135A2 (en) * 2003-04-09 2004-10-21 Asterion Limited Cytokine polypeptides and antibodies containing a signal sequence for the attachement of glycosylphosphatidylinositol
US20080026008A1 (en) * 2006-07-27 2008-01-31 Clark Tibbs Bacteriophage DNA vaccine vector

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905857D0 (en) * 1989-03-14 1989-04-26 Hoffmann La Roche Plasmodium merozoite rhoptries antigen
NL9100869A (nl) * 1991-05-17 1992-12-16 Univ Lausanne Dictyostelide expressievector en werkwijze voor het tot expressie brengen van een gewenst eiwit.
BR9400600A (pt) * 1994-02-17 1995-10-24 Finep Financiadora De Estudos Processos para produção de uma protéina recombinante e/ou de glicosilfosfatidilinositol (GPI) em células de microorganismos eucariontes e para a obtenção de leveduras de S. cerevisae; célula de levedura sequência de nucleotídios; meio de cultura; medicamento ou vacina; e produto dos ditos processos

Also Published As

Publication number Publication date
NL1001348C2 (en) 1996-10-28
HUP9802238A2 (hu) 1999-01-28
JPH11504215A (ja) 1999-04-20
NO974924D0 (no) 1997-10-24
CZ291013B6 (cs) 2002-11-13
AU714808B2 (en) 2000-01-13
NZ307195A (en) 1999-07-29
NO974924L (no) 1997-12-19
AU5648196A (en) 1996-11-18
IL118021A0 (en) 1996-08-04
PL323078A1 (en) 1998-03-02
ZA963269B (en) 1996-10-25
CZ337897A3 (cs) 1998-04-15
WO1996034105A1 (en) 1996-10-31
CA2218987A1 (en) 1996-10-31
HUP9802238A3 (en) 2000-03-28
EP0826050A1 (en) 1998-03-04
US6113917A (en) 2000-09-05

Similar Documents

Publication Publication Date Title
Sjölander et al. The serum albumin-binding region of streptococcal protein G: a bacterial fusion partner with carrier-related properties
HUP0104889A2 (hu) Telomerázból származó antigenikus peptidek
AUPM566794A0 (en) Process and product
WO1997030158A3 (fr) Proteine recombinante contenant un fragment c-terminal de msp-1 de plasmodium
GB2143830A (en) Expression of plasmodium falciparum polypeptides from cloned cdna
CA2093659A1 (en) Dna sequence encoding bovine .alpha.-lactalbumin and methods of use
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
NZ230526A (en) Peptide containing an epitope of circumsporozoite protein of plasmodium falciparum fusion protein, dna sequences
BR9604989A (pt) Polipeptídeos modificados para imunogenicidade aperfeiçoada e processo de sua produção
DE69520943D1 (de) Malariapeptide
IL75788A (en) Peptide comprising a repeated sequence of four amino acids,which sequence occurs in plasmodium falciparum circumsporozoite protein
EP0329257A3 (en) Method for producing recombinant protein derived from the circumsporozoite gene of plasmodium falciparum
IL90134A0 (en) Gene for encoding a human malaria vaccine antigen,malarial vaccines and pharmaceutical compositions
DK0638316T3 (da) Rekombinante adenovirusvacciner
PT97876A (pt) Processo para a producao de uma nova proteina
KR920012116A (ko) 말라리아 항원 hrpii 및 serp의 부분-서열들을 함유하는 보호적 플라스모듐 팔시파룸 하이브리드 단백질, 이의 제조방법 및 이의 용도
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
MY107451A (en) Cloning and expression of a rhoptry associated protein of p.falciparum
EP0392820A3 (en) Plasmodium circumsporozoite protein analogs lacking repeat sequences
ZA896942B (en) Allelic variants of plasmodium falciparum merozoite surface antigen
ATE201046T1 (de) Polypeptide und dafür kodierende dns, die mit humanen malariaparasiten assoziiert sind
ATE110741T1 (de) Synthetische peptide, die immunologische aktivität zeigen, benutzbar, um eine impfung gegen malaria vorzubereiten.
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
MY106275A (en) Plasmodium merozoite rhoptries antigen and derivatives thereof.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved
B09B Patent application refused [chapter 9.2 patent gazette]